Therapeutic angiogenesis using vascular endothelial growth factor

Asian Cardiovascular and Thoracic Annals

Volumn 12, Issue 2, 2004, Pages 173-181

  Ye, Lei ^a   Haider, Husnain K ^a   Jiang, Shu Jia ^a   Sim, Eugene K W ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; LIPOSOME; PLACEBO; PLASMID DNA; RECOMBINANT VASCULOTROPIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIUM CELL; GENE THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM;

EID: 3543042573     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230401200221     Document Type: Review

References (86)

1. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 2003;10:285-91.
2. Stegmann TJ, Hoppert T, Schneider A, Gemeinhardt S, Kocher M, Ibing R, et al. Induction of myocardial neo-angiogenesis by human growth factors. A new therapeutic approach in coronary heart disease. Herz 2000;25:589-99.
3. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, Sellke FW. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.
4. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
5. Rajanayagam MA, Shou M, Thirumurti V, Lazarous DF, Quyyumi AA, Goncalves L, et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol 2000;35:19-26.
6. Iwakura A, Fujita M, Ikemoto M, Hasegawa K, Nohara R, Sasayama S, et al. Myocardial ischemia enhances the expression of acidic fibroblast growth factor in human pericardial fluid. Heart Vessels 2000;15:112-6.
7. Kusumanto YH, Hospers GA, Mulder NH, Tio RA. Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review. Int J Cardiovasc Intervent 2003;5:27-34.
8. Laham RJ, Li J, Tofukuji M, Post M, Simons M, Sellke FW. Spatial heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins. Ann Vasc Surg 2003;17:245-2.
9. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003;92:436-9.
10. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901.
11. Lee LY, Patel SR, Hackett NR, Mack CA, Polce DR, El-Sawy T, et al. Focal angiogenic therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000;69:14-23.
12. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation. J Am Coll Cardiol 2000;35:1323-30.
13. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, Kaneda Y, et al. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 2001;104 (Suppl I):207-12.
14. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-9.
15. Tanaka E, Hattan N, Ando K, Ueno H, Sugio Y, Mohammed MU, et al. Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits. J Thorac Cardiovasc Surg 2000;120:720-8.
16. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996;94:1074-82.
17. Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, et al. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999;44:294-302.
18. Hariawala MD, Horowitz JR, Esakof D, Sheriff DD, Walter DH, Keyt B, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996;63:77-82.
19. Lopez JJ, Laham RJ, Stamler A, Pearlman JD, Bunting S, Kaplan A, et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998;40:272-81.
20. 165 gene transfer. Gene Ther 2002;9:1676-81.
21. Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998;115:168-76.
22. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-65.
23. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-4.
24. Laitinen M, Hartikainen J, Hiltunen MO, Eranen J, Kiviniemi M, Narvanen O, et al. Catheter mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000;11:263-70.
25. Kalka C, Tehrani H, Laudenberg B, Vale PR, Isner JM, Asahara T, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 2000;70:829-34.
26. 165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000;102:965-74.
27. Vale PR, Losordo DW, Milliken CE, Esakof DD, Maysky M, Lathi K, et al. Long-term (> 2 years) results of a phase I/II trial of direct myocardial gene transfer of phVEGF165 demonstrate sustained safety and efficacy in patients with end-stage coronary artery disease. Circulation 2001 (Suppl II);104-361.
28. Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, et al. Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther 2002;13:1595-603.
29. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-74.
30. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999;230:466-70.
31. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107:2677-683.
32. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
33. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
34. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
35. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999;237:59-83.
36. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
37. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. Nature 1995;376:62-6.
38. Taipale J, Makinen T, Arighi E, Kukk E, Karkkainen M, Alitalo K. Vascular endothelial growth factor receptor-3. Curr Top Microbiol Immunol 1999;237:85-96.
39. Fong GH, Zhang L, Bryce DM, Peng J. Increased haemangioblast commitment, not vascular disorganization, is the primary defect in Flt-1 knocked-out mice. Development 1999;126:3015-25.
40. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia: modulation of gene expression by nitric oxide. J Clin Invest 1995;1798-807.
41. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, Flk-1 and Flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996;207:H1803-11.
42. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from Flt tyrosine kinase, a receptor for vascular endothelial growth factor. Oncogene 1995;10:135-47.
43. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001;159:993-1008.
44. Gille H, Kowalski J, Li B, Lecouter J, Moffat B, Zioncheck T, et al. Analysis of biological effects and signaling properties of Flt-1 and KDR. A re-assessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-30.
45. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, et al. Identification of vascular endothelial growth factor determinants for binding KDR and Flt-1 receptor: generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996;271:5638-46.
46. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an infract-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
47. Takashima S, Asakura M, Matsumura Y, Kim J, Takeda H, Kitakaze M. Targeting of both neuropilin-1 and -2 genes result in major impairment of development angiogenesis. Circulation 2001;104(Suppl II):33.
48. Berra E, Pages G, Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 2000;19:139-45.
49. Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, et al. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000;902:187-200.
50. Laughner E, Taghavi P, Chiles K, Mahon P, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1 mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
51. Sodhi A, Montaner S, Miyazaki H, Gutkind JS. MAPK and AKT act cooperatively but independently on hypoxia inducible factor-1α in rasV12 up-regulation of VEGF. Biochem Biophys Res Commun 2001; 287:292-300.
52. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995;27:12607-13.
53. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin-like growth factor-1 in colorectal carcinoma. J Biol Chem 1996;271:29483-8.
54. Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 1996;120:944-7.
55. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M Misciglia N, et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-55.
56. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
57. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-41.
58. Frank S, Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes and during coetaneous would repair. FASEB J 1999;14:2002-14.
59. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, et al. Nitric oxide induces vascular endothelial growth factor-A synthesis by vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:659-66.
60. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000;95:189-97.
61. Jozkowicz A, Cooke JP, Guevara I, Huk I, Funovics P, Pachinger O, et al. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc Res 2001;51:773-83.
62. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997;3:879-86.
63. Heeschen C, Jang J, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates angiogenesis and promotes tumor growth. Nat Med 2001;7:833-9.
64. Kitlinska J, Lee EW, Movafagh S, Pons J, Zukowska Z. Neuropeptide Y-induced angiogenesis in aging. Peptides 2002;23:71-7.
65. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23.
66. Manninen HI, Makinen K. Gene therapy techniques for peripheral arterial disease. Cardiovasc Intervent Radiol 2002;25:98-108.
67. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000;101:118-21.
68. Saito K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J, et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001;37:616-23.
69. Tio RA, Tkebuchava T, Scheuermann TH, Lebherz C, Magner M, Kearny M, et al. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium. Hum Gene Ther 1999;10:2953-60.
70. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-6.
71. Koh GY, Kim SJ, Klug MG, Park K, Soonpaa MH, Field LJ. Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 1995;95:114-21.
72. Haider KH, Jiang SJ, Ye L, Teh M, Chou F, Law PK, et al. Human myoblasts carrying hVEGF165as cellular assist device for myocardial therapeutics. Circulation 2002;106 (Suppl II):148.
73. Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, et al. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation 2003;107:461-8.
74. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003;107:1322-8.
75. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999;237:59-83.
76. Zachary I, Mathur A, Yla-Herttuala S, Martin J. Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2000;20:1512-20.
77. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280: C1375-86.
78. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by over expression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002;90:966-73.
79. Kastrup J. Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy? Curr Gene Ther 2003;3:197-206.
80. Unger EF, Banai S, Shoo M, Lazarous DF, Jaklitsch MT, Scheinowitz M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994;266:H1588-95.
81. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355:213-22.
82. Urbich C, Aicher D. Homeobox A9 regulates endothelial cells migration and angiogenesis. Circulation 2002;106 (Suppl II):268.
83. Rebar EJ, Huang Y, Hickey R, Nath AK, Meoli D, Nath S, et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 2002;8:1427-32.
84. Matsunaga T, Warltier DC, Tessmer J, Weihrauch D, Simons M, Chilian WM. Expression of VEGF and angiopoietin-1 and -2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol 2003;285:H352-8.
85. Shyu KG, Chang H, Isner JM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hind limb ischemia. Life Sci 2003;73:563-79.
86. Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF. Nat Med 2003;9:604-13.